Development and implementation of a performance improvement project in adult intensive care units: overview of the Improving Medicine Through Pathway Assessment of Critical Therapy in Hospital-Acquired Pneumonia (IMPACT-HAP) study.
BACKGROUND
In 2005 the American Thoracic Society and Infectious Diseases Society of America (ATS/IDSA) published guidelines for managing hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), and healthcare-associated pneumonia (HCAP). Although recommendations were evidence based, collective guidelines had not been validated in clinical practice and did not provide specific tools for local implementation. We initiated a performance improvement project designated Improving Medicine Through Pathway Assessment of Critical Therapy in Hospital-Acquired Pneumonia (IMPACT-HAP) at four academic centers in the United States. Our objectives were to develop and implement the project, and to assess compliance with quality indicators in adults admitted to intensive care units (ICUs) with HAP, VAP, or HCAP.


METHODS
The project was conducted in three phases over 18 consecutive months beginning 1 February 2006: 1) a three-month planning period for literature review to create the consensus pathway for managing nosocomial pneumonia in these ICUs, a data collection form, quality performance indicators, and internet-based repository; 2) a six-month implementation period for customizing ATS/IDSA guidelines into center-specific guidelines via educational forums; and 3) a nine-month post-implementation period for continuing education and data collection. Data from the first two phases were combined (pre-implementation period) and compared with data from the post-implementation period.


RESULTS
We developed a consensus pathway based on ATS/IDSA guidelines and customized it at the local level to accommodate formulary and microbiologic considerations. We implemented multimodal educational activities to teach ICU staff about the guidelines and continued education throughout post-implementation. We registered 432 patients (pre- vs post-implementation, 274 vs 158). Diagnostic criteria for nosocomial pneumonia were more likely to be met during post-implementation (247/257 (96.1%) vs 150/151 (99.3%); P = 0.06). Similarly, empiric antibiotics were more likely to be compliant with ATS/IDSA guidelines during post-implementation (79/257 (30.7%) vs 66/151 (43.7%); P = 0.01), an effect that was sustained over quarterly intervals (P = 0.0008). Between-period differences in compliance with obtaining cultures and use of de-escalation were not statistically significant.


CONCLUSIONS
Developing a multi-center performance improvement project to operationalize ATS/IDSA guidelines for HAP, VAP, and HCAP is feasible with local consensus pathway directives for implementation and with quality indicators for monitoring compliance with guidelines.
The Ohio State University, 410 West 10th Ave, N-1150 Doan Hall Columbus, OH 43210, USA. Julie.Mangino@osumc.edu
Julie E
JE
Mangino
Paula
P
Peyrani
Kimbal D
KD
Ford
Daniel H
DH
Kett
Marcus J
MJ
Zervos
Verna L
VL
Welch
Ernesto G
EG
Scerpella
Julio A
JA
Ramirez
D000046:Academic Medical Centers; D000328:Adult; D000368:Aged; D003422:Critical Care / Q000592:standards*; D003428:Cross Infection / Q000628:therapy*; D005240:Feasibility Studies; D005260:Female; D019983:Guideline Adherence; D006801:Humans; D007362:Intensive Care Units / Q000458:organization & administration* / Q000592:standards; D008297:Male; D008875:Middle Aged; D053717:Pneumonia, Ventilator-Associated / Q000628:therapy*; D017410:Practice Guidelines as Topic; D058996:Quality Improvement / Q000458:organization & administration*; D019984:Quality Indicators, Health Care; D014481:United States
Chest. 2005 Oct;128(4):2778-87
16236955
Pharmacotherapy. 2006 Sep;26(9):1358-68
16945060
Chest. 2004 Jun;125(6):2224-31
15189945
Crit Care Med. 2002 Nov;30(11):2407-12
12441746
Infect Control Hosp Epidemiol. 2008 Jun;29(6):525-33
18510462
Chest. 1992 Jun;101(6):1644-55
1303622
Chest. 2004 May;125(5):1791-9
15136392
Chest. 2006 Jul;130(1):251-60
16840410
Crit Care Med. 2009 Jan;37(1):159-66
19050600
Ann Intern Med. 2009 Jan 6;150(1):19-26
19124816
Am J Respir Crit Care Med. 1996 May;153(5):1711-25
8630626
Am J Respir Crit Care Med. 2005 Feb 15;171(4):388-416
15699079
Am J Respir Crit Care Med. 2000 Aug;162(2 Pt 1):505-11
10934078
Crit Care Med. 2001 Jun;29(6):1109-15
11395584
Chest. 2008 Aug;134(2):447-456
18682466
Crit Care Med. 2009 Jan;37(1):350-2
19112300
Chest. 2010 Dec;138(6):1356-62
20558550
Can Respir J. 2001 Jul-Aug;8(4):255-60
11521141
Clin Infect Dis. 2010 Apr 1;50(7):945-52
20175690
Clin Infect Dis. 2009 Dec 15;49(12):1868-74
19911940
Chest. 2006 Sep;130(3):787-93
16963676
Am J Infect Control. 2008 Jun;36(5):309-32
18538699
Lancet Infect Dis. 2011 Mar;11(3):181-9
21256086
Clin Infect Dis. 2009 Jul 1;49(1):72-7
19480582